Psyence Biomedical
PBM

$0.1277

8.13%

Market Cap: $2.13M

About: Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.

Employees: 10

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

1.88% more ownership

Funds ownership: 8.43% [Q1] → 10.31% (+1.88%) [Q2]

0% more funds holding

Funds holding: 10 [Q1] → 10 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

66% less capital invested

Capital invested by funds: $831K [Q1] → $280K (-$551K) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for PBM.

See Analyst Rankings

Financial journalist opinion

Based on 9 articles about PBM published over the past 30 days

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has successfully completed the first site initiation visit at the first Australian clinical trial site for PBM's Phase IIb study of nature derived (non-synthetic) psilocybin as a potential treatment for Adjustment Disorder in the Palliative Care context.

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorders (SUDs) through exclusive IP licensing agreement with Psylabs for its botanical psilocybin product Announced acquisition of synthetic psilocybin-based drug developer Clairvoyant, further bolstering AUD development program Two Phase II data readouts anticipated in 2025 NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd.

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the “Determination Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had not regained compliance with the Market Value of Listed Securities (“MVLS”) Requirement and the Market Value of Publicly Held Shares (“MVPHS”) requirement by September 9, 2024.

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Patient screening to be initiated imminently; first subject expected to be randomized into the study in October Patient screening to be initiated imminently; first subject expected to be randomized into the study in October

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD)

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that the registration statement pertaining to its previously announced $25 million equity line of credit (the “ELOC”) with White Lion Capital, LLC, (“White Lion”) on Form F-1 has been declared effective by the U.S. Securities and Exchange Commission (SEC) on August 28, 2024. As previously disclosed, this 24-month arrangement allows Psyence Biomed to sell up to $25 million in shares to White Lion, subject to certain conditions.

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of nature-derived psilocybin-based therapeutics, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024 in New York.

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Vancouver, British Columbia and New York, New York--(Newsfile Corp. - August 13, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi"), a GMP-approved, Health Canada licensed psychedelics pharmaceutical manufacturer specializing in botanical psilocybin and MDMA, and Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence"), a developer of nature-derived psilocybin-based therapeutics, are pleased to announce that the companies have entered into a non-binding Letter of Intent ("LOI").

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

See News Rankings